This is a clinical-stage biopharmaceutical company working on creating a new kind of antibiotics. These antibiotics are specifically designed to combat infections caused by bacteria that are considered high-priority threats by organisations like the World Health Organization (WHO), the United States Centers for Disease Control and Prevention (CDC) and the United States Food and Drug Administration (FDA). Acurx Pharmaceuticals focuses on developing antibiotics that target the DNA polymerase IIIC enzyme (Pol IIIC), a key player in the DNA replication process in Gram-positive bacterial cells. The company's research and development pipeline includes antibiotic candidates in various stages that aim to treat infections caused by specific bacteria strains, including Clostridium difficile, vancomycin-resistant Enterococcus, methicillin-resistant Staphylococcus and antibiotic-resistant Streptococcus.
Freetrade is your gateway to commission-free investing. Join over 1.6 million users using the Best online trading platform, as voted at the British Bank Awards for six years running.
Freetrade does not provide investment advice and individual investors should make their own decisions or seek independent advice. The value of investments can go down as well as up and you may receive back less than your original investment. Past performance is not a reliable indicator of future returns. Freetrade is a trading name of Freetrade Limited, which is a member firm of the London Stock Exchange and is authorised and regulated by the Financial Conduct Authority. Registered in England and Wales (no. 09797821).
© 2025 Freetrade, All rights reserved. The Apple logo is a trademark of Apple Inc. App Store is a service mark of Apple Inc. Google Play and the Google Play logo are trademarks of Google LLC.